Trials / Completed
CompletedNCT00205478
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-702 |
Timeline
- Start date
- 2005-06-01
- Completion
- 2006-02-01
- First posted
- 2005-09-20
- Last updated
- 2007-12-07
Locations
43 sites across 9 countries: Bulgaria, Croatia, Czechia, Poland, Russia, Serbia and Montenegro, Slovakia, Slovenia, Ukraine
Source: ClinicalTrials.gov record NCT00205478. Inclusion in this directory is not an endorsement.